Orthofix International N.V. (OFIX) Sets New 1-Year High at $49.95
Orthofix International N.V. (NASDAQ:OFIX) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $49.95 and last traded at $49.90, with a volume of 61,229 shares. The stock had previously closed at $49.81.
Several brokerages have recently weighed in on OFIX. SunTrust Banks, Inc. began coverage on Orthofix International N.V. in a report on Tuesday, May 23rd. They set a “buy” rating and a $49.00 target price on the stock. Ladenburg Thalmann Financial Services began coverage on Orthofix International N.V. in a report on Wednesday, June 14th. They set a “buy” rating and a $53.25 target price on the stock. Langenberg & Company restated a “buy” rating and set a $53.25 target price on shares of Orthofix International N.V. in a report on Wednesday, June 14th. BTIG Research began coverage on Orthofix International N.V. in a report on Wednesday, June 21st. They set a “buy” rating and a $52.00 target price on the stock. Finally, Zacks Investment Research upgraded Orthofix International N.V. from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Seven analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $52.75.
The firm has a 50-day moving average of $46.85 and a 200 day moving average of $42.39. The company has a market cap of $897.23 million, a price-to-earnings ratio of 115.64 and a beta of 0.22.
Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The company had revenue of $108.90 million during the quarter, compared to analysts’ expectations of $102.94 million. During the same quarter in the prior year, the company posted $0.41 EPS. The business’s revenue was up 4.6% on a year-over-year basis. On average, equities analysts predict that Orthofix International N.V. will post $1.56 earnings per share for the current year.
In other news, CEO Brad Mason sold 2,733 shares of the stock in a transaction on Monday, August 21st. The shares were sold at an average price of $48.10, for a total value of $131,457.30. Following the completion of the transaction, the chief executive officer now owns 188,053 shares in the company, valued at approximately $9,045,349.30. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Raymond Fujikawa sold 6,364 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $47.06, for a total transaction of $299,489.84. Following the completion of the transaction, the insider now owns 31,084 shares of the company’s stock, valued at approximately $1,462,813.04. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Pinebridge Investments L.P. raised its stake in shares of Orthofix International N.V. by 2.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock valued at $111,000 after buying an additional 53 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Orthofix International N.V. by 79.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock valued at $165,000 after buying an additional 1,571 shares in the last quarter. Mason Street Advisors LLC acquired a new position in shares of Orthofix International N.V. in the 1st quarter valued at $159,000. Municipal Employees Retirement System of Michigan acquired a new position in shares of Orthofix International N.V. in the 2nd quarter valued at $196,000. Finally, Quantbot Technologies LP acquired a new position in shares of Orthofix International N.V. in the 1st quarter valued at $175,000. Institutional investors own 94.43% of the company’s stock.
WARNING: This piece was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/07/orthofix-international-n-v-ofix-sets-new-1-year-high-at-49-95.html.
About Orthofix International N.V.
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.